Association of mutation patterns in GyrA and ParC genes with quinolone resistance levels in lactic acid bacteria

Journal of Antibiotics

Volumn 68, Issue 2, 2015, Pages 81-87

  Li, Shaoying ^a   Li, Zhen ^a   Wei, Wan ^b   Ma, Chunyan ^a   Song, Xiaomin ^a   Li, Shufen ^a   He, Wenying ^a   Tian, Jianjun ^a   Huo, Xiaoyan ^a  

^a INNER MONGOLIA AGRICULTURAL UNIVERSITY   (China)

^b Food and Cosmetic Authority of Inner Mongolia   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); NORFLOXACIN; ANTIINFECTIVE AGENT; DNA TOPOISOMERASE IV; LACTIC ACID; QUINOLONE DERIVATIVE; YOGHURT;

AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; BACTERIAL STRAIN; BROTH DILUTION; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GYRA GENE; INCIDENCE; INHIBITION ZONE; LACTIC ACID BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARC GENE; PRACTICE GUIDELINE; PRIORITY JOURNAL; DAIRY PRODUCT; DRUG EFFECTS; ENTEROCOCCUS; GENETICS; ISOLATION AND PURIFICATION; LACTOBACILLUS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION;

BACTERIA (MICROORGANISMS); ENTEROCOCCUS; ENTEROCOCCUS DURANS; LACTOBACILLUS;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; CULTURED MILK PRODUCTS; DNA GYRASE; DNA TOPOISOMERASE IV; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS; LACTIC ACID; LACTOBACILLUS; MICROBIAL SENSITIVITY TESTS; MUTATION; NORFLOXACIN; QUINOLONES; YOGURT;

EID: 84928471649     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2014.113     Document Type: Article

References (37)

1. Hummel, A. S., Hertel, C., Holzapfel, W. H. & Franz, C. M. Antibiotic resistances of starter and probiotic strains of lactic acid bacteria. Appl. Environ. Microbiol. 73, 730-739 (2007).
2. Caplice, E. & Fitzgerald, G. F. Food fermentations: role of microorganisms in food production and preservation. Int. J. Food Microbiol. 50, 131-149 (1999).
3. Leroy, F. & De Vuyst, L. Lactic acid bacteria as functional starter cultures for the food fermentation industry. Trends Food Sci. 15, 67-78 (2004).
4. Wood, B. J. & Holzapfel, W. H. N. (eds) in The Genera of Lactic Acid Bacteria, Vol. 2. Springer (Blackie Academic and Professional), London, UK, 1995.
5. Carr, F. J., Chill, D. & Maida, N. The lactic acid bacteria: a literature survey. Crit. Rev. Microbiol. 28, 281-370 (2002).
6. Chorostowska-Wynimko, J., Krotkiewski, M., Radomska-Les̈niewska, D., Sokolnicka, I. & Skopińska-Rózewska, E. The synergistic effect of lactic acid bacteria and alkylglycerols on humoral immunity in mice. Int. J. Tissue React. 23, 81-87 (2000).
7. Dàvila, E., Saguer, E., Toldrà, M., Carretero, C. & Parés, D. Preservation of porcine blood quality by means of lactic acid bacteria. Meat Sci. 73, 386-393 (2006).
8. Shin, H. S., Chung, M. J., Kim, J. E., Lee, K. O. & Ha, N. J. Lactic acid bacteria affect serum cholesterol levels, harmful fecal enzyme activity, and fecal water content. Lipids Health Dis. 8, 21 (2009).
9. Joint, F. A. O. WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food (London, Ontario, Canada, 30 April 2002).
10. Krasteva, P. V. Molecular engineering: DNA nanoLEGOlogy. Nat. Methods 9, 640-641 (2012).
11. Méchali, M. Methods in DNA replication. Methods 57, 139 (2012).
12. Zhang, Y. & Gong, F. DNA repair. Methods 48, 1-2 (2009).
13. Collin, F., Karkare, S. & Maxwell, A. Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. Appl. Microbiol. Biotechnol. 92, 479-497 (2011).
14. Xia, R. R., Guo, X. H., Zhang, Y. Z. & Xu., H. Quinolones and the mechanism of quinolone resistance in bacteria. Chin. J. Antibiot. 35, 255-261 (2010).
15. Hummel, A., Holzapfel, W. H. & Franz, C. M. Characterisation and transfer of antibiotic resistance genes from enterococci isolated from food. Syst. Appl. Microbiol. 30, 1-7 (2007).
16. Landman, D. & Quale, J. M. Management of infections due to resistant enterococci: a review of therapeutic options. J. Antimicrob. Chemother. 40, 161-170 (1997).
17. Leclercq, R. Enterococci acquire new kinds of resistance. Clin. Infect. Dis. 24(Suppl. 1), 80-S84 (1997).
18. Morrison, D., Woodford, N. & Cookson, B. Enterococci as emerging pathogens of humans. J. Appl. Microbiol. 83, 89S-99S (1997).
19. Murray, B. E. The life and times of the Enterococcus. Clin. Microbiol. Rev. 3, 46-65 (1990).
20. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Third Informational Supplement. M100-S23 (Clinical and Laboratory Standards Institute, 2013).
21. Kawamura, Y. et al. First Streptococcus agalactiae isolates highly resistant to quinolones, with point mutations in gyrA and parC. Antimicrob. Agents Chemother. 47, 3605-3609 (2003).
22. Klein, G., Pack, A. & Reuter, G. Antibiotic resistance patterns of enterococci and occurrence of vancomycin-resistant enterococci in raw minced beef and pork in Germany. Appl. Environ. Microbiol. 64, 1825-1830 (1998).
23. Brisse, S. et al. Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones. Antimicrob. Agents Chemother. 43, 2513-2516 (1999).
24. Hooper, D. C. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin. Infect. Dis. 31(Suppl. 2), S24-S28 (2000).
25. Schmitz., F. J. et al. Characterisation of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on cipro-floxacin MIC. Antimicrob. Agents Chemother. 42, 1249-1252 (1998).
26. Pulido, R. P. et al. Resistance to antimicrobial agents in lactobacilli isolated from caper fermentations. Antonie Van Leeuwenhoek. 88, 277-281 (2005).
27. Zhou, J. S., Pillidge, C. J., Gopal, P. K. & Gill, H. S. Antibiotic susceptibility profiles of new probiotic Lactobacillus and Bifidobacterium strains. Int. J. Food. Microbiol. 98, 211-217 (2005).
28. European Commission. Opinion of the Scientific Committee on Animal Nutrition on the criteria for assessing the safety of micro-organisms resistant to antibiotics of human clinical and veterinary importance (European Commission, Health and Consumer Protection Directorate General, Directorate C, Scientific Opinions, Brussels, Belgium, 2002).
29. FEEDAP, P. Opinion of the scientific panel on additives and products or substances used in animal feed on the updating of the criteria used in assessment of bacteria for resistance to antibiotics of human and veterinary importance. EFSA J. 223, 1-12 (2005).
30. Zarazaga, M. et al. In vitro activities of ketolide HMR3647, macrolides, and other antibiotics against Lactobacillus, Leuconostoc, and Pediococcus isolates. Antimicrob. Agents Chemother. 43, 3039-3041 (1999).
31. Fournier, B. & Hooper, D. C. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity. Antimicrob. Agents Chemother. 42, 121-128 (1998).
32. Bébéar, C. M., Charron, A., Bové, J. M., Bébéar, C. & Renaudin, J. Cloning and nucleotide sequences of the Topoisomerase IV parC and parE genes of Mycoplasma hominis. Antimicrob. Agents Chemother. 42, 2024-2031 (1998).
33. Patel, S. N. et al. Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada. Ann. Clin. Microbiol. Antimicrob. 9, 3 (2010).
34. Cabral, J. H. M. et al. Crystal structure of the breakage-reunion domain of DNA gyrase. Nature 388, 903-906 (1997).
35. Gillespie, S. H., Voelker, L. L., Ambler, J. E., Traini, C. & Dickens, A. Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation. Microb. Drug Resist. 9, 17-24 (2003).
36. Li, X. Z. & Nikaido, H. Efflux-mediated drug resistance in bacteria. Drugs 64, 159-204 (2004).
37. Li, X. Z. & Nikaido, H. Efflux-mediated drug resistance in bacteria. Drugs 69, 1555-1623 (2009).